Category Archives: Biotechnology

The 41 rating InvestorsObserver gives to Adaptimmune Therapeutics PLC - ADR (ADAP) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 65 percent of stocks in the Biotechnology industry, ADAPs 41 overall rating means the stock scores better than 41 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 41 means the stock is more attractive than 41 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Adaptimmune Therapeutics PLC - ADR (ADAP) stock is lower by -5.07% while the S&P 500 has gained 0.08% as of 10:51 AM on Tuesday, Jun 1. ADAP is down -$0.26 from the previous closing price of $5.03 on volume of 315,861 shares. Over the past year the S&P 500 is up 37.69% while ADAP is down -58.93%. ADAP lost -$0.93 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Adaptimmune Therapeutics PLC - ADR (ADAP) Stock.

Follow this link:
Is Adaptimmune Therapeutics PLC - ADR (ADAP) a Smart Choice in Biotechnology Tuesday? - InvestorsObserver

Cellect Biotechnology Ltd - ADR (APOP) stock has gained 17.83% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.

InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.

Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

Cellect Biotechnology Ltd - ADR (APOP) stock is trading at $3.37 as of 9:53 AM on Tuesday, Jun 1, a rise of $0.23, or 7.51% from the previous closing price of $3.13. The stock has traded between $3.26 and $3.48 so far today. Volume today is less active than usual. So far 173,401 shares have traded compared to average volume of 487,516 shares.

To see InvestorsObserver's Sentiment Score for Cellect Biotechnology Ltd - ADR click here.

Cellect Biotechnology Ltd is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies. The company is developing its first product based on its ApoGraft technology platform, the ApoTainer kit that utilizes FasL- apoptotic protein.

Click Here to get the full Stock Score Report on Cellect Biotechnology Ltd - ADR (APOP) Stock.

See the article here:
Is it Time to Dump Cellect Biotechnology Ltd - ADR (APOP) Stock After it Has Gained 17.83% in a Week? - InvestorsObserver

TEHRAN The Biotechnology Development Council will launch 129 production projects with the aim of saving up to $1.44 billion of foreign currency, IRNA reported on Monday.

The projects include the production of 27 biological medicine, 12 vaccine development, and 90 pharmaceutical raw materials through knowledge-based companies. The Vice Presidency for Science and Technology will also support the plans financially and commercially.

The Biotechnology Development Council is also working to accelerate the implementation of such programs by concluding a memorandum of understanding with capable companies to set production priorities, accelerate and lead start-ups, and provide financial support.

Currently, over 5,700 knowledge-based companies are active in Iran, manufacturing diverse products to meet the needs of the domestic market while saving large amounts of foreign currency, in addition to export the items.

The fields of aircraft maintenance, steel, pharmaceuticals, and medical equipment, oil, and gas are among the sectors that researchers in technology companies have engaged in, leading to import reduction.

Irani ranks 12th in biotechnology

Iran is ranked 12th in the world and first in West Asia in terms of biotechnology, as 9.5 percent of the income of knowledge-based companies and more than 60 percent of their exports are related to biotechnology.

Foreign exchange savings of $1 billion per year by producing 22 biopharmaceuticals, gaining the first rank in biotechnology products and vaccines in West Asia, and the presence among the top five biotechnology producers in Asia are among the countrys achievements, Mostafa Ghanei, secretary of the biotechnology development office of the Vice Presidency for Science and Technology, said in October 2020.

So far, 27 biotechnology medicines, 12 vaccine projects, 90 pharmaceutical raw materials, and 55 projects in agriculture and food security have been implemented in order to gain a 3 percent market share and biotechnology assistance to the development of the economy, he explained.

Some 8 major companies are responsible for managing the country's 117 priority products in the fields of biopharmaceuticals, pharmaceutical raw materials, vaccines, probiotics, equipment, and chemical drugs, he emphasized.

Pharmaceutical capabilities

Mohammad Reza Shanehsaz, head of the Food and Drug Administration, said in January that the Iranian pharmaceutical industry and scientists are capable of producing any kind of medicine over a two-year period.

Health Minister Saeed Namaki said that some 97 percent of the whole medicine consumed in the country is produced domestically and only 3 percent is imported.

Sourena Sattari Vice President for Science and Technology, also said that Iran plays a leading role in the field of biotechnology in the region, with the production of 24 biotech medicine.

Ismail Ghaderifar, head of the center for strategic technologies development of the vice presidency of science and technology added that under sanctions in the most difficult conditions, Iran combatted the pandemic and knowledge-based companies could make the country independent. Moreover, they managed to produce pharmaceutical items required by the country's health system.

FB/MG

Continued here:
Biotechnology projects aim to save $1.44 billion - Tehran Times

The 46 rating InvestorsObserver gives to Intellia Therapeutics Inc (NTLA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 79 percent of stocks in the Biotechnology industry, NTLAs 46 overall rating means the stock scores better than 46 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Intellia Therapeutics Inc (NTLA) stock is trading at $66.66 as of 10:11 AM on Monday, May 24, an increase of $3.18, or 5.01% from the previous closing price of $63.48. The stock has traded between $64.42 and $67.32 so far today. Volume today is light. So far 91,818 shares have traded compared to average volume of 1,170,123 shares.

Click Here to get the full Stock Score Report on Intellia Therapeutics Inc (NTLA) Stock.

Read the original:
Is Intellia Therapeutics Inc (NTLA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Aerpio Pharmaceuticals Inc (ARPO) is near the top in its industry group according to InvestorsObserver. ARPO gets an overall rating of 64. That means it scores higher than 64 percent of stocks. Aerpio Pharmaceuticals Inc gets a 96 rank in the Biotechnology industry. Biotechnology is number 111 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Aerpio Pharmaceuticals Inc (ARPO) stock is lower by -15.35% while the S&P 500 has risen 1.15% as of 1:43 PM on Monday, May 24. ARPO is down -$0.31 from the previous closing price of $2.02 on volume of 3,709,381 shares. Over the past year the S&P 500 is up 40.50% while ARPO has risen 116.46%. ARPO lost -$0.08 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Aerpio Pharmaceuticals Inc (ARPO) Stock.

Follow this link:
Where Does Aerpio Pharmaceuticals Inc (ARPO) Stock Fall in the Biotechnology Field After It Is Up 3.01% This Week? - InvestorsObserver

89bio Inc (ETNB) is near the top in its industry group according to InvestorsObserver. ETNB gets an overall rating of 47. That means it scores higher than 47 percent of stocks. 89bio Inc gets a 79 rank in the Biotechnology industry. Biotechnology is number 111 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

89bio Inc (ETNB) stock is down -9.37% while the S&P 500 is higher by 1.04% as of 11:07 AM on Monday, May 24. ETNB is lower by -$2.12 from the previous closing price of $22.62 on volume of 79,063 shares. Over the past year the S&P 500 has risen 40.36% while ETNB is lower by -21.46%. ETNB lost -$3.09 per share the over the last 12 months.

Click Here to get the full Stock Score Report on 89bio Inc (ETNB) Stock.

See the original post:
Where Does 89bio Inc (ETNB) Stock Fall in the Biotechnology Field After It Is Down -5.75% This Week? - InvestorsObserver

Kura Oncology Inc (KURA) is near the top in its industry group according to InvestorsObserver. KURA gets an overall rating of 45. That means it scores higher than 45 percent of stocks. Kura Oncology Inc gets a 74 rank in the Biotechnology industry. Biotechnology is number 111 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 45 would rank higher than 45 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Kura Oncology Inc (KURA) stock is lower by -0.2% while the S&P 500 is higher by 1.07% as of 1:19 PM on Monday, May 24. KURA is lower by -$0.05 from the previous closing price of $22.53 on volume of 397,242 shares. Over the past year the S&P 500 is higher by 40.39% while KURA is higher by 37.47%. KURA lost -$1.73 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Kura Oncology Inc (KURA) Stock.

Read more:
Where Does Kura Oncology Inc (KURA) Stock Fall in the Biotechnology Field After It Is Down -9.82% This Week? - InvestorsObserver

Biotechnology equities are slumping to start 2021, with the S&P Biotechnology Select Industry Index down 10% year-to-date.

Mergers and acquisitions activity, which are typically vibrant in the biotech space, are also in a funk. Yet many experts believe biotech consolidation is poised to pick up the pace in the second half of 2021. If that happens, the ALPSMedical Breakthroughs ETF (SBIO)could reap the rewards.

SBIO components have market values of $200 million to $5 billion at the time of inclusion in the fund. Even the higher end of that range is a sweet spot for cash-rich pharmaceuticals companies looking to replenish drug pipelines and fend off patent cliffs. With the aforementioned decline by the S&P Biotechnology Select Industry Index, some pharmaceuticals could now be on the prowl for takeover targets.

Last month, Moodys Investors Service said Amgen, Bristol Meyers Squibb, Johnson & Johnson, and Merck are among the companies with the resources and potential need to engage in acquisitions without harming their credit ratings. As just one example, J&J has north of $25 billion in cash, meaning any number of SBIO firms would be easily digestible for the Dow component.

M&A start to pick up after [three to six months]of a large drawdown and as prices normalize for sellers, Jefferies analyst Michael Yee wrote in a note cited by Josh Nathan-Kazis for Barrons.

The lethargic start to 2021 for biotechnology consolidation comes after the pace of deal-making slowed in 2020. Entering this year, PwC forecast up to $275 billion in transactions in the life sciences arena.

SBIOs underlying index mandate that member firms have at least one drug or therapy in either Phase II or Phase III U.S. Food and Drug Administration (FDA) clinical trials. That limits some of the volatility associated with pre-trial and Phase I only names. Additionally, it makes the funds roster potentially fertile ground for suitors. Approximately 20 SBIO components have been acquired since the ETF came to market in late 2014.

The extent to which biotechnology M&A perks up and how it affects SBIO remains to be seen. However, Jefferies Yee identifies Fate Therapeutics Inc. (FATE) SBIOs biggest holding as a possible takeover target.

Other biotech ETFs to consider include the VanEck Vectors Biotech ETF (BBH), iShares Biotechnology ETF (IBB), and the Virtus LifeSci Biotech Clinical Trials ETF (BBC).

For more on cornerstone strategies, visit our ETF Building Blocks Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

See original here:
As Biotech Consolidation Heats up, 'SBIO' Could Be a Winner - ETF Trends

The 49 rating InvestorsObserver gives to Cytokinetics, Inc. (CYTK) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 83 percent of stocks in the Biotechnology industry, CYTKs 49 overall rating means the stock scores better than 49 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 49 means the stock is more attractive than 49 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Cytokinetics, Inc. (CYTK) stock is trading at $24.28 as of 11:13 AM on Thursday, May 20, an increase of $0.52, or 2.19% from the previous closing price of $23.76. The stock has traded between $23.43 and $24.30 so far today. Volume today is 761,118 compared to average volume of 778,232.

Click Here to get the full Stock Score Report on Cytokinetics, Inc. (CYTK) Stock.

Read the original post:
Is Cytokinetics, Inc. (CYTK) a Winner in the Biotechnology Industry? - InvestorsObserver

The 52 rating InvestorsObserver gives to DBV Technologies ADR Representing 0.5 Ord Shs (DBVT) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 89 percent of stocks in the Biotechnology industry, DBVTs 52 overall rating means the stock scores better than 52 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 52 means the stock is more attractive than 52 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

DBV Technologies ADR Representing 0.5 Ord Shs (DBVT) stock is trading at $5.86 as of 11:03 AM on Monday, May 24, a drop of -$0.24, or -3.93% from the previous closing price of $6.10. The stock has traded between $5.82 and $5.92 so far today. Volume today is low. So far 69,160 shares have traded compared to average volume of 138,523 shares.

Click Here to get the full Stock Score Report on DBV Technologies ADR Representing 0.5 Ord Shs (DBVT) Stock.

Read more:
Is DBV Technologies ADR Representing 0.5 Ord Shs (DBVT) a Good Buy in the Biotechnology Industry? - InvestorsObserver